Last reviewed · How we verify
NCT04136106
The Incidence of Infection in Treatment of Low-dose IL-2 of SLE Patients
trial testing IL-2 in Infection in 500 participants. Status unknown.
1 November 2021
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 July 2019 |
| Primary completion | 1 November 2021 |
| Estimated completion | 30 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- IL-2 — full drug profile →
Conditions studied
- Infection — all drugs for Infection →
Sponsor
Peking University People's Hospital
Who can join
Adults 18 to 80, any sex, with Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
IL-2 is a pleiotropic cytokine which can regulate or stimulate the differentiation and function of CD4+, CD8+ and NK cells. An opened-labelled trial and a retrospective study have indicated the incidence of infection is lower in the treatment of low-dose IL-2 combined with corticosteroid and immunosuppressor. We are going to conduct a multi-center prospective observational study to verify the above results.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A glimpse into the application of the immunomodulatory effect of IL-2 in systemic lupus erythematosus.
Xia X, Qu R. · · 2025 · PMID 40337274 · DOI 10.3389/fmed.2025.1552473
Verify or expand the search:
- PubMed search for NCT04136106
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IL-2
Trials testing the same drug.
- NCT06158828 — Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML · Phase 1, PHASE2 · recruiting
- NCT06302062 — Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors · Phase 1 · recruiting
- NCT05336409 — A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies · Phase 1 · terminated
- NCT05603013 — Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 f · Phase 2 · unknown
- NCT05400122 — Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Recepto · Phase 1 · suspended
Other recruiting trials for Infection
Currently open trials in the same condition.
- NCT07358117 — Viral Infections of the Central Nervous System: Diagnosis and Clinical Outcome · active not recruiting
- NCT07110636 — Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients · NA · recruiting
- NCT06806709 — Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial) · NA · recruiting
- NCT06974162 — Metagenomics for Ocular Inflammation · recruiting
- NCT07370948 — Study of the Antibiotic-resistance Profile of Enterobacterales Isolated From Rectal Mucosal Buffer of PrEP Subjects · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04136106 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 23 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04136106.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing